# Prevascar in African Continental Group Scarring

> **NCT01115868** · PHASE1 · UNKNOWN · sponsor: **Renovo** · enrollment: 56 (estimated)

## Conditions studied

- Scarring

## Interventions

- **DRUG:** Prevascar 5ng
- **DRUG:** Prevascar 25ng
- **DRUG:** Prevascar 100ng
- **DRUG:** Prevascar 250ng

## Key facts

- **NCT ID:** NCT01115868
- **Lead sponsor:** Renovo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-04
- **Primary completion:** 2012-06
- **Final completion:** 2012-08
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2011-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01115868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01115868, "Prevascar in African Continental Group Scarring". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT01115868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*